Novavax, Inc. Stock Nasdaq
Equities
US6700021040
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | 846M | Sales 2025 * | 986M | Capitalization | 657M |
---|---|---|---|---|---|
Net income 2024 * | -112M | Net income 2025 * | -90M | EV / Sales 2024 * | 0.17 x |
Net cash position 2024 * | 510M | Net cash position 2025 * | 482M | EV / Sales 2025 * | 0.18 x |
P/E ratio 2024 * |
-6.82
x | P/E ratio 2025 * |
-125
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.34% |
Latest transcript on Novavax, Inc.
Managers | Title | Age | Since |
---|---|---|---|
John Jacobs
CEO | Chief Executive Officer | 57 | 23-01-22 |
John Trizzino
PSD | President | 64 | 14-03-09 |
James Kelly
DFI | Director of Finance/CFO | 58 | 21-08-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Rodgers
BRD | Director/Board Member | 57 | 22-10-28 |
Gregg Alton
BRD | Director/Board Member | 58 | 20-10-31 |
David Mott
BRD | Director/Board Member | 58 | 20-06-15 |
1st Jan change | Capi. | |
---|---|---|
+25.69% | 48.09B | |
+46.90% | 40.62B | |
-3.46% | 40.43B | |
-6.20% | 28.36B | |
+9.17% | 24.89B | |
-20.42% | 19.01B | |
+28.07% | 12.09B | |
+0.17% | 11.88B | |
-1.24% | 11.8B |